Results 91 to 100 of about 53,296 (261)

Bisphenol A and Its Analogs: Toxicity Analysis in Mouse and Rat Liver—A Review

Journal of Applied Toxicology, EarlyView.
ABSTRACT Bisphenol A (BPA) and its analogs are widely recognized for their use in industry and plastic manufacturing. Consequently, humans and animals are continually exposed to various substances in their daily lives. This review evaluates the hepatic toxicity of BPA and its analogs in mice and rats, with particular emphasis on molecular mechanisms ...
Sevda Bagdatli, Muhammed Canik, Gizem Gencay, Nurbanu Zengin, Tarık Dinc, Nazan Deniz Yön   +5 more
wiley   +1 more source

Dual biologic therapy in inflammatory bowel disease, a retrospective cohort study of vedolizumab and anti‐tumor necrosis factor alpha therapy in children

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Despite advances in pediatric inflammatory bowel disease (PIBD) with biologics, remission rates remain at 47%–60% with loss‐of‐response rates at 60%–68%. Evidence for efficacy of dual biologic therapy (DBT) with anti‐tumor necrosis factor alpha therapy (anti‐TNF‐α)‐ vedolizumab (VDZ) for children refractory to anti‐TNF‐α therapy is ...
Jonathan E. M. O'Donnell, Carlie Bolles, Claire R. Reilly, Manal Morgan, Christopher Burgess, Fariha Balouch, Peter J. Lewindon   +6 more
wiley   +1 more source

The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan, Christian Wysocki, Bhaskar Gurram   +2 more
wiley   +1 more source

Acneiform eruption associated with Janus kinase inhibitors in pediatric inflammatory bowel disease: Case series and clinical management guidance

JPGN Reports, EarlyView.
Abstract Janus kinase inhibitors (JAKi) are increasingly used for refractory inflammatory bowel disease (IBD) in pediatric patients but are associated with significant dermatologic adverse effects. Acneiform eruptions have been reported in up to 30% of adults, with a greater incidence suspected in adolescents.
Tina H. Tran, Daniel Park, Regina‐Celeste Ahmad, Malika Goel, Sofia Verstraete, Sabina Ali   +5 more
wiley   +1 more source

Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review

JEADV Clinical Practice, EarlyView.
This systematic review identifies consistent clinical patterns of alopecia areata associated with IL‐17 and IL‐23 inhibitors, most frequently involving secukinumab and ustekinumab. Disease severity varied widely, and management often required biologic discontinuation or therapeutic switching.
Isabella Kamholtz, Simonetta I. Gaumond, Joaquin J. Jimenez   +2 more
wiley   +1 more source

Profile of pacritinib and its potential in the treatment of hematologic disorders

Journal of Blood Medicine, 2014
Eleftheria Hatzimichael, Evangelos Tsolas, Evangelos Briasoulis Department of Haematology, University Hospital of Ioannina, Ioannina, Greece Abstract: Pacritinib (previously known as SB-1518) is an innovative selective inhibitor of Janus kinase 2 and ...
Hatzimichael E, Tsolas E, Briasoulis E
doaj  

Nail Lichen Planus in Children ‐ Epidemiology, Pathogenesis, Clinical Presentation, and Treatment

JEADV Clinical Practice, EarlyView.
ABSTRACT Nail lichen planus (NLP) is a chronic inflammatory disorder that, while rare in children compared to adults, represents a significant cause of pediatric nail dystrophy that requires early recognition to prevent permanent scarring and nail loss.
Francesca Pampaloni, Matilde Iorizzo
wiley   +1 more source

Janus Kinase Inhibitors in Dermatology

Indian Journal of Drugs in Dermatology, 2019
Janus kinase (JAK) inhibitors are a new addition in the armamentarium of drugs in the treatment of autoimmune dermatoses. They have proven to be valuable in treating a variety of inflammatory dermatoses with lesser side effects compared to their biological counterparts. This review throws light on JAK inhibitors and their role
openaire   +1 more source

When Treatment Meets Natural History: Understanding Early Dermatitis‐Related Adverse Events in Systemic Atopic Dermatitis Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Biologics and Janus kinase (JAK) inhibitors have transformed the management of atopic dermatitis (AD), yet some patients experience early worsening of disease activity during treatment initiation. In clinical trials, these events are typically recorded as treatment‐emergent adverse events (TEAEs), most commonly coded as “atopic dermatitis”. We
Diego Ruiz Dasilva, Alondra Soto‐Gonzalez, Haya Alkiswani, Graham H. Litchman, Harrison Nguyen, Gil Yosipovitch, Firas George Hougeir, Matthew Zirwas, David Cotter, Brad Glick, E. James Song, Christopher G. Bunick, Neal Bhatia, Adam Friedman, Leon Kircik, Mona Shahriari, Peter Lio, James Del Rosso   +17 more
wiley   +1 more source

Real‐World Effectiveness and Safety of Topical Ruxolitinib in Adolescents With Vitiligo: A 52‐Week Retrospective Study

JEADV Clinical Practice, EarlyView.
Topical ruxolitinib 1.5% cream was assessed in 39 adolescents with non‐segmental vitiligo. Median T‐VASI fell at week 24 (n = 34) and week 52 (n = 18), with repigmentation most pronounced on the face: 55.6% reached F‐VASI50 at week 52. Few adverse events were recorded, all mild application‐site reactions in 4 of 39 patients.
L. Coronella, V. Picone, C. Costa, M. Napolitano   +3 more
wiley   +1 more source